Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.

[1]  R. López-Vélez,et al.  Old and new challenges in Chagas disease. , 2015, The Lancet. Infectious diseases.

[2]  J. Mateus,et al.  Inhibitory Receptor Expression on CD8+ T Cells Is Linked to Functional Responses against Trypanosoma cruzi Antigens in Chronic Chagasic Patients , 2015, The Journal of Immunology.

[3]  S. Yusuf,et al.  Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. , 2015, The New England journal of medicine.

[4]  L. M. Magalhães,et al.  Immunoregulatory networks in human Chagas disease , 2014, Parasite immunology.

[5]  I. Molina,et al.  Trypanosoma cruzi infection in a non-endemic country: epidemiological and clinical profile. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  S. Epiphanio,et al.  Chagas Disease: Still Many Unsolved Issues , 2014, Mediators of inflammation.

[7]  Fernando Salvador,et al.  Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. , 2014, The New England journal of medicine.

[8]  J. Ramsey,et al.  Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review , 2014, Expert review of anti-infective therapy.

[9]  C. Morillo,et al.  Cytokine Profiling in Chagas Disease: Towards Understanding the Association with Infecting Trypanosoma cruzi Discrete Typing Units (A BENEFIT TRIAL Sub-Study) , 2014, PloS one.

[10]  R. Tarleton,et al.  Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. , 2013, The Journal of antimicrobial chemotherapy.

[11]  M. Teixeira,et al.  Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease , 2012, Seminars in Immunopathology.

[12]  A. Teixeira-Carvalho,et al.  Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens , 2012, BMC Infectious Diseases.

[13]  R. López-Vélez,et al.  EuroTravNet: imported Chagas disease in nine European countries, 2008 to 2009. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  P. Chiodini,et al.  Chagas disease in European countries: the challenge of a surveillance system. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  R. López-Vélez,et al.  Chagas disease in Latin American migrants: a Spanish challenge. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  J. Sztajzel,et al.  Prevalence, Clinical Staging and Risk for Blood-Borne Transmission of Chagas Disease among Latin American Migrants in Geneva, Switzerland , 2010, PLoS neglected tropical diseases.

[17]  R. López-Vélez,et al.  Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. , 2009, The Journal of antimicrobial chemotherapy.

[18]  R. Tarleton,et al.  Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  S. Montgomery,et al.  An estimate of the burden of Chagas disease in the United States. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  A. Teixeira-Carvalho,et al.  Strategy to Assess the Overall Cytokine Profile of Circulating Leukocytes and its Association with Distinct Clinical Forms of Human Chagas Disease , 2008, Scandinavian journal of immunology.

[21]  A. Teixeira-Carvalho,et al.  Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. , 2008, Microbes and infection.

[22]  Robert H Gilman,et al.  Evaluation and treatment of chagas disease in the United States: a systematic review. , 2007, JAMA.

[23]  Rodolfo Viotti,et al.  Long-Term Cardiac Outcomes of Treating Chronic Chagas Disease with Benznidazole versus No Treatment , 2006, Annals of Internal Medicine.

[24]  J. Silver,et al.  Parameters influencing membrane CD14 expression and soluble CD14 levels in sepsis. , 2001, European journal of medical research.

[25]  E. Segura,et al.  Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. , 1998, The American journal of tropical medicine and hygiene.

[26]  Simonne Almeida e Silva,et al.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection , 1996, The Lancet.